Scientists weaponize common cold virus to attack cancer in groundbreaking trial
NCT ID NCT06977737
Summary
This is the first time a new experimental drug called ATTR-01 is being tested in people. The drug is made from a modified common cold virus designed to specifically infect cancer cells and deliver an immune-boosting therapy to help the body fight the tumor. The trial will first find a safe dose and then see if the treatment can shrink tumors in adults with certain advanced solid cancers who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
, St James' University Hospital
RECRUITINGLeeds, United Kingdom
-
Beatson West of Scotland Cancer Centre
RECRUITINGGlasgow, Scotland, United Kingdom
-
Churchill Hospital
RECRUITINGOxford, United Kingdom
-
START Barcelona
RECRUITINGBarcelona, Spain
-
Start Fjd
RECRUITINGMadrid, Spain
-
Start Hm Ciocc
RECRUITINGMadrid, Spain
-
Velindre Cancer Centre
RECRUITINGCardiff, Wales, United Kingdom
Conditions
Explore the condition pages connected to this study.